FREMONT, Calif., Jan. 19, 2011 /PRNewswire/ — WaferGen
Biosystems, Inc. (OTC Bulletin Board:
WGBS), a leading developer of state-of-the-art genomic analysis
systems, today announced that it has appointed world-renowned
clinical genomics cancer researcher Arul M. Chinnaiyan, M.D.,
Ph.D., to its Scientific Advisory Board.
Dr. Chinnaiyan is a recognized leader in the use of biomarkers
in the clinic to choose appropriate therapies for cancer patients.
Biomarkers are characteristics that are measured and
evaluated as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic
intervention. Dr. Chinnaiyan has led the characterization of
a number of biomarkers of prostate cancer including AMACR, EZH2,
hepsin, and sarcosine. His laboratory identified recurrent ETS gene
fusions in prostate cancer, potentially redefining the molecular
basis of prostate cancer as well as other common epithelial
cancers. His laboratory also developed Oncomine (www.oncomine.org), a popular
cancer profiling bioinformatics resource.
Biomarker expertise is important to WaferGen as the WaferGen
SmartChip system, with its 5000+ nano-well format, is designed to
provide faster, more cost-effective biomarker identification and
validation for multiple samples and patients.
“WaferGen understands what is needed for high-throughput
biomarker profiling in order to complement targeted therapies.
I am eager to share my clinical knowledge to help build even
better genomic analysis products,” said Dr. Chinnaiyan.
“Dr. Chinnaiyan’s insight into the use of biomarkers in the
clinic will be invaluable to support WaferGen’s development of
impactful products for genomics analysis including current product
selection as well as future molecular diagnostics programs,” said
Alnoor Shivji, Waf